Table 5.

The relationship between galcanezumab serum concentration, ADA titer and capsaicin-induced DBF upon four biweekly galcanezumab dose administration.

Subject	ADA Titer	Serum Galcanezumab (ng/mL)	DBF Pre-capsaicin	DBF Post-capsaisin	Fold increase
701	ND	1,765	0.48	2.32	4.8
703	1:20	2,338	0.64	2.54	4.0
704	1:40	4,012	0.65	1.00	1.5
705	1:40	1,935	0.75	2.13	2.8
706	ND	2,599	0.75	1.66	2.2
707	ND	2,145	0.59	1.35	2.3
709	1:160	2,795	0.91	2.91	3.2

PK, ADA, and DBF measurements shown are on Day 176 from the beginning of dosing, 133 days after the last galcanezumab dose administration.

ADA, Anti-drug antibodies; DBF, dermal blood flow; ND, not detected; PK, pharmacokinetics.